{"doi":"10.1111/hiv.70105","title":"Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the <scp>OPERA</scp> cohort","abstract":"Abstract Objectives To compare the virologic effectiveness and discontinuation of the commonly prescribed fixed‐dose combination 3‐drug and 2‐drug regimens, bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir/lamivudine (DTG/3TC), in virologically suppressed individuals in routine clinical care in the US. Methods From the OPERA cohort, ART‐experienced, virologically suppressed (viral load &lt;200 copies/mL) adults with HIV who switched to B/F/TAF or DTG/3TC (01AUG2020‐30JUN2022) were followed through 31DEC2022, death, loss to follow‐up or discontinuation. Cox proportional hazard models with stabilized inverse probability of treatment weights were used to assess the association between regimen and time to confirmed virologic failure (cVF 200 ; 2 viral loads ≥200 copies/mL or 1 viral load ≥200 copies/mL + discontinuation) or time to discontinuation. Results A total of 3512 B/F/TAF users were followed for a median of 16 months (IQR: 11, 22); 2327 DTG/3TC users were followed for a median of 15 months (IQR: 10, 21). cVF 200 was observed among 2% of B/F/TAF and 3% of DTG/FTC users, for an adjusted hazard ratio of 0.84 (95% CI: 0.59, 1.18) for B/F/TAF compared with DTG/3TC. Regimen discontinuation was observed among 17% of B/F/TAF and 19% of DTG/3TC users, for an adjusted hazard ratio of 0.83 (95% CI: 0.73, 0.94) for B/F/TAF compared with DTG/3TC. Treatment‐related reasons for discontinuation represented 6% of B/F/TAF and 9% of DTG/3TC discontinuations. Conclusions In this large US cohort, both B/F/TAF and DTG/3TC were well tolerated and effective treatment options among virologically suppressed individuals in routine clinical care, although DTG/3TC tended to be discontinued faster than B/F/TAF.","journal":"HIV Medicine","year":2025,"id":573754,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9471,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":539530,"name":"Laurence Brunet","orcid":"0000-0001-8467-4835","position":1,"is_corresponding":false},{"id":539531,"name":"Jennifer S Fusco","orcid":"0000-0003-1556-811X","position":2,"is_corresponding":false},{"id":1481289,"name":"Michael Sension","orcid":null,"position":3,"is_corresponding":false},{"id":1480912,"name":"Megan S. Dunbar","orcid":"0000-0001-9250-5126","position":4,"is_corresponding":false},{"id":745079,"name":"Joshua Gruber","orcid":"0000-0003-3016-1940","position":5,"is_corresponding":false},{"id":566991,"name":"Douglas T. Dieterich","orcid":"0000-0001-7786-8594","position":6,"is_corresponding":false},{"id":1480913,"name":"Gregory Fusco","orcid":"0000-0002-6834-784X","position":7,"is_corresponding":false},{"id":1087720,"name":"Gerald Pierone","orcid":"0000-0003-0159-7243","position":0,"is_corresponding":true}],"reference_count":35,"raw_metadata":null,"created_at":"2026-07-19T02:57:36.753600Z","pmid":"40884203","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}